A large, randomized U.K. trial found “no clinical benefit” of hydroxychloroquine to treat hospitalized COVID-19 patients, researchers announced Friday.
“It doesnt work,” declared Martin Landray, one of the lead researchers, at a briefing. Patients receiving hydroxychloroquine died at about the same rate — about one in four — as those receiving regular care in a randomized trial being conducted by the University of Oxford and the U.K. National Health Service.
Researchers said theyre no longer giving patients the malaria drug in the so-called RECOVERY trial, which will continue to evaluate three other treatments as potential coronavirus fixes.
For anyone whos hospitalized, “hydroxychloroquine is not the right treatment,” Landray said.
Researchers reviewed their data earlier than planned following a request Thursday by the U.K.s drugs regulator.
Its the latest twist for the controversial drug, championed by U.S. President Donald Trump, among others. Last month, a massive observational study published in the Lancet suggested it increased the risk of death, prompting the World Health Organization to pause its study of hydroxychloroquine.
As questions about that study grew, leading to the Lancets retraction on Thursday, the WHO restarted its hydroxychloroquine study, saying the data from current randomized trials dont show it causing extra harm.
Peter Horby, the other principal investigator, said he informed the WHO Friday morning about their determinations.
However, the U.N. health bodys Chief SciRead More – Source
